Nevertheless, whether OSI has superior survival benefits and higher activity against T790M-positive NSCLC and multiple central nervous system (CNS) metastases after failure of initial EGFR-TKI treatment compared with afatinib (AFA) remains unknown [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.